Aldeyra Therapeutics Receives FDA Complete Response Letter for Reproxalap in Dry Eye Disease

Key Developments Investors Must Know

• FDA Issues Complete Response Letter (CRL) for Reproxalap: The U.S. Food and Drug Administration (FDA) has issued a CRL to Aldeyra Therapeutics for the New Drug Application (NDA) of reproxalap, its investigational therapy for dry eye disease. The FDA cited a lack of “substantial evidence” from “adequate and well-controlled investigations” to support the proposed labeling claims. There were significant concerns regarding the inconsistency of study results and the reliability and meaningfulness of the positive findings. The totality of evidence from clinical trials did not support the effectiveness of reproxalap for this indication.
• No Safety or Manufacturing Issues: Importantly, the FDA did not identify any safety or manufacturing concerns in its review. This limits the regulatory setback to efficacy and trial design, rather than product safety or production.
• FDA Feedback and Next Steps: While the FDA recommended that Aldeyra further explore the reasons for trial failures and potentially identify patient populations or conditions where reproxalap may be effective, it did not request additional clinical trials or confirmatory evidence at this time. Aldeyra does not plan to initiate further clinical trials and will request a Type A meeting with the FDA to clarify the path forward for NDA approval. Target timing for this meeting is within 30 days, as per PDUFA guidelines.
• Label Negotiation Status: Aldeyra noted that the FDA provided label drafts in December 2025 and again in March 2026, but the company does not believe label negotiations were completed.
• Financial Update: As of December 31, 2025, Aldeyra reported cash, cash equivalents, and marketable securities totaling \$70 million. Management expects this cash position to support operations into 2028, providing a runway that allows the company to address regulatory feedback and potentially pursue other strategic options.

Analysis for Shareholders and Potential Impact on Share Value

This development is highly significant and likely to be materially price-sensitive for Aldeyra Therapeutics (Nasdaq: ALDX) shareholders. The CRL for reproxalap—a late-stage and potentially high-value asset—represents a major regulatory hurdle that could delay or diminish the commercial prospects of the company’s lead candidate for dry eye disease. The FDA’s lack of confidence in the efficacy data, coupled with noted inconsistencies in clinical results, raises substantial uncertainties regarding the future approval and market entry of reproxalap in this indication.

While the absence of safety or manufacturing issues is a minor positive, the core challenge remains the demonstrated efficacy and consistency of clinical results. Notably, the FDA did not demand new clinical trials at this stage, which may provide a faster regulatory path if Aldeyra can adequately address the agency’s concerns through additional analyses or focused labeling.

For investors, the company’s strong cash position provides a buffer, potentially reducing immediate financial risk. However, the regulatory setback may impact near-term valuation, as reproxalap was anticipated as a key revenue driver. The outcome of the upcoming Type A meeting with the FDA will be crucial for determining next steps, timelines, and the likelihood of eventual approval.

Company Statement

“To the thousands of American and Canadian patients who participated in our clinical trials and to the tens of millions of patients with dry eye disease worldwide, I want to assure you that we will work with urgency to support the FDA in enabling market access to what is, to our knowledge, the only drug with clinical activity within minutes of administration in patients with dry eye disease, a condition that is today treated with medications that require weeks or months of treatment to achieve even modest improvement,” said Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company focused on developing therapies for immune-mediated diseases. Its approach centers on modulating protein systems, aiming to optimize multiple pathways while minimizing toxicity. The company’s pipeline includes RASP (reactive aldehyde species) modulators such as ADX-248, ADX-246, and reproxalap, as well as ADX-2191, a novel formulation of intravitreal methotrexate for primary vitreoretinal lymphoma and retinitis pigmentosa.

Forward-Looking Statements and Risks

The company’s statements regarding future plans, FDA interactions, and the regulatory path for reproxalap are forward-looking and subject to risks and uncertainties. These include regulatory outcomes, the potential need for additional data, market acceptance, funding requirements, and the competitive landscape. Investors are encouraged to review the company’s filings with the SEC for a comprehensive discussion of risks.

Contact Information

Investor & Media Contact: Laura Nichols
Tel: (781) 257-3060
Email: [email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making investment decisions. The information is based on public filings and statements as of the date of publication and may be subject to change without notice.

View Aldeyra Therapeutics, Inc. Historical chart here